Prometheus Biosciences, Inc.
Prometheus Biosciences, Inc. (RXDX) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
rxdx · stock forecast · 11 analysts (3M) · FMP · updated Sep 19, 2025
Analyst Rating & Consensus
Based on 11 Wall Street analysts in the past 3 months
Hold
11 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$200
Consensus
$139
-30.7% upside
Low
$67.00
Median: $142 · Last Close: $199.92
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$138.57
-30.7% upside
High Target
$200
0.0%
Low Target
$67
-66.5%
Current Price
$199.92
as of today
Based on analyst price targets, the RXDX stock price prediction for the next 12 months ranges from $67 to $200. The consensus RXDX price forecast of $138.57 implies -30.7% upside from the current price of $199.92.
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $199.89 | ↓ 0.02% |
1-day model range: $199.68–$200.09. Peak: $200.09 (-0.02%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · RXDX · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2023-05-10 | RBC Capital | Maintains | Sector Perform→Perform |
| 2023-05-10 | Jefferies | Downgrade ↓ | Buy→Hold |
| 2023-04-18 | RBC Capital | Downgrade ↓ | Outperform→Perform |
| 2023-04-18 | Credit Suisse | Downgrade ↓ | Outperform→Neutral |
| 2023-04-18 | Piper Sandler | Downgrade ↓ | Overweight→Neutral |
| 2023-04-18 | Wells Fargo | Downgrade ↓ | Overweight→Equal Weight |
| 2023-04-17 | Guggenheim | Downgrade ↓ | Buy→Neutral |
| 2023-04-17 | Stifel | Downgrade ↓ | Buy→Hold |
| 2023-03-06 | Guggenheim | Maintains | Buy→Buy |
| 2023-03-01 | Oppenheimer | Maintains | Outperform→Outperform |
Wall Street analysts have recently issued updated ratings on Prometheus Biosciences, Inc. (RXDX) stock. Of the recent 43 rating actions, 1 were upgrades and 8 were downgrades. 11 analysts currently cover RXDX.
Analyst Recommendation Trends
RXDX analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
—
Revenue Next Year
—
EPS This Year
—
EPS Next Year
—
EPS ForecastReported vs Estimated
Analysts forecast RXDX EPS of $— for the current fiscal year, based on estimates from 0 analysts. The RXDX revenue forecast is — for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The RXDX stock forecast is supported by two independent data sources: analyst consensus ratings from 11 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus RXDX price target is $138.57 (-30.7% upside), with an analyst consensus of Hold.
The RXDX short-term stock prediction for tomorrow is $199.89 (-0.02%).
Prometheus Biosciences, Inc. trades on NASDAQ under the ticker RXDX. The RXDX stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 36% of covering analysts.
Frequently asked questions
RXDX forecast · 8 questionsAccording to 11 Wall Street analysts, the average 12-month RXDX price target is $138.57, with a high forecast of $200.00 and a low of $67.00. The median price target is shown in the chart above when available. This implies -30.7% potential upside from the current price of $199.92.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.